The first-in-human (FIH) study of IMC-002 is planned to be initiated during the 1st half of 2020. The purpose of the study is to assess the safety and tolerability of IMC-002 and determine the recommended Phase 2 dose (RP2D) of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas.
over 4 years ago
Preclinical • IO biomarker
|
CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD14 (CD14 Molecule)